Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003871 · ClinicalTrials.gov registry record · Phase 2

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
10
Study locations

NCT00003871: Completed Phase 2 study of Prostate Cancer, sponsored by Eastern Cooperative Oncology Group.

NCT00003871 is a Phase 2 study of Prostate Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003871, a Phase 2 study of Prostate Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
10
Study locations

Study Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • BIOLOGICAL fowlpox virus vaccine vector
  • BIOLOGICAL recombinant vaccinia prostate-specific antigen vaccine

Study Locations (10)

Indiana

  • Indiana University Cancer Center - Indianapolis
  • Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • University of Pittsburgh Cancer Institute - Pittsburgh

Wisconsin

  • Veterans Affairs Medical Center - Madison - Madison
  • University of Wisconsin Comprehensive Cancer Center - Madison

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

New Jersey

  • Cancer Institute of New Jersey - New Brunswick

New York

  • Albert Einstein Comprehensive Cancer Center - The Bronx

Tennessee

  • Vanderbilt Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 1999-09-24
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003871

The ClinicalTrials.gov registry entry for NCT00003871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which fowlpox virus vaccine vector is the first listed.

NCT00003871 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Indiana, Pennsylvania, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00003871 about?

NCT00003871 is a clinical study titled "PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of different regimens of PSA vaccines in treating patients who have advanced prostate cancer.

What is the current status of trial NCT00003871?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1999-09-24.

What conditions does trial NCT00003871 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00003871?

The interventions under investigation include: fowlpox virus vaccine vector (BIOLOGICAL), recombinant vaccinia prostate-specific antigen vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003871?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003871 being conducted?

This trial has 10 study locations across Indiana, Massachusetts, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.